This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Ironwood (IRWD) Q1 Earnings Beat Estimates, Linzess Volume Up
by Zacks Equity Research
Ironwood (IRWD) reports better-than-expected results, wherein both earnings and revenues beat estimates. The strong momentum of Linzess continues with 10% growth in prescription demand.
AZNPositive Net Change IRWDPositive Net Change ABBVNegative Net Change
biotechnology earnings medical
Apellis (APLS) Q1 Earnings Miss, Empaveli & Syfovre Fuel Growth
by Zacks Equity Research
Apellis Pharmaceuticals' (APLS) loss in the first quarter is wider than estimates. Empaveli and Syfovre boost product revenues for the company.
APLSNegative Net Change RCUSPositive Net Change ALLOPositive Net Change
biotechnology earnings medical
Intellia (NTLA) Beats on Q1 Earnings, Gives Pipeline Update
by Zacks Equity Research
Intellia's (NTLA) first-quarter earnings beat estimates. The company provides updates on its gene-editing pipeline.
REGNNegative Net Change NTLAPositive Net Change ALLOPositive Net Change
biotechnology crispr earnings gene-therapy medical
Corcept (CORT) Misses on Q1 Earnings, Revises 2023 Sales Guidance
by Zacks Equity Research
Corcept (CORT) first-quarter earnings miss estimates, while revenues beat the same. The company gives updates on its pipelines and raises revenue guidance for 2023.
MRKNegative Net Change CORTNegative Net Change ALLOPositive Net Change
biotechnology earnings medical
Zoetis (ZTS) Q1 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Zoetis' (ZTS) first-quarter 2023 earnings beat estimates, while revenues miss the same. The company reiterates its financial guidance for 2023.
ZTSNegative Net Change RCUSPositive Net Change ALLOPositive Net Change
biotechnology earnings medical vaccines
Regeneron (REGN) Q1 Earnings & Sales Top, Eylea Sales Decline
by Zacks Equity Research
Regeneron (REGN) beats earnings and sales estimates in first-quarter 2023 fueled by Dupixent. However, sales of the lead drug Eylea declined yet again.
REGNNegative Net Change SNYNegative Net Change RHHBYNegative Net Change BAYRYNegative Net Change
biotechnology pharmaceuticals
Amarin's (AMRN) Q1 Earnings Top, Vascepa Sales Fall
by Zacks Equity Research
Amarin's (AMRN) first-quarter 2023 earnings and revenues beat estimates. Vascepa sales decline.
AMRNNegative Net Change RCUSPositive Net Change ALLOPositive Net Change
biotechnology earnings medical
Repligen (RGEN) Beats on Q1 Earnings, Lowers 2023 Guidance
by Zacks Equity Research
Repligen's (RGEN) first-quarter earnings and revenues beat estimates.
RGENPositive Net Change RCUSPositive Net Change ALLOPositive Net Change
biotechnology earnings medical
5 Stocks With Recent Price Strength That Still Have Upside
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are META, CMG, ACLX, HROW and PRG.
CMGNegative Net Change HROWPositive Net Change PRGNegative Net Change METAPositive Net Change ACLXPositive Net Change
biotechnology finance medical restaurants tech-stocks
2 Medical Stocks to Buy Before Earnings
by Shaun Pruitt
Cardinal Health (CAH) and Ligand Pharmaceuticals (LGND) are two healthcare companies that investors certainly want to watch going into their quarterly reports.
CAHPositive Net Change LGNDPositive Net Change
biotechnology earnings genetics medical pharmaceuticals
Incyte (INCY) Q1 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Incyte's (INCY) first-quarter 2023 earnings and revenues miss estimates due to higher patient deductibles and inventory challenges.
NVSNegative Net Change LLYNegative Net Change INCYNegative Net Change LGNDPositive Net Change
biotechnology medical
Biotech/Drug Stocks' Q1 Earnings Due May 3: UTHR, PCRX & More
by Ekta Bagri
Let us take a look at what's in store for biotech/drug stocks UTHR, PCRX, CORT, AMRN and IONS, which are scheduled to report on May 3.
UTHRPositive Net Change PCRXPositive Net Change AMRNNegative Net Change CORTNegative Net Change IONSNegative Net Change
biotechnology biotechs pharmaceuticals
CRISPR (CRSP) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On CRISPR's (CRSP) first-quarter earnings call, investors will likely focus on its pipeline, especially its lead candidate exa-cel, due to the absence of marketed drugs.
VRTXPositive Net Change AMRNNegative Net Change CRSPNegative Net Change ALLOPositive Net Change
biotechnology earnings gene-therapy medical
Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Zoetis' (ZTS) key drugs like Apoquel, Cytopoint, Simparica Trio, Librela and Solensia are likely to have driven first-quarter sales.
AMRNNegative Net Change ZTSNegative Net Change RETAPositive Net Change ALLOPositive Net Change
biotechnology earnings medical
Intercept (ICPT) Q1 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Intercept (ICPT) reports wider-than-expected loss in the first quarter of 2023. Revenues rise year over year.
LGNDPositive Net Change ICPTPositive Net Change VKTXPositive Net Change
biotechnology earnings medical
Gilead's (GILD) Q1 Earnings Miss, Veklury Sales Plunge
by Zacks Equity Research
Gilead's (GILD) Q1 earnings and sales miss estimates due to lower Veklury sales.
SNYNegative Net Change GSKNegative Net Change NVONegative Net Change GILDNegative Net Change
biotechnology pharmaceuticals
5 Must-Buy High-Flying Mid-Cap Stocks Ahead of Q1 Earnings
by Nalak Das
We have narrowed our search to five stocks that are set to report first-quarter 2023 earnings results. These are: SHAK, WING, AMK, PRI and CERT.
PRINegative Net Change SHAKNegative Net Change WINGNegative Net Change CERTNegative Net Change
biotechnology finance insurance restaurants
Bristol-Myers (BMY) Q1 Earnings Beat, Revlimid Generics Hurt Sales
by Zacks Equity Research
Bristol-Myers' (BMY) first-quarter 2023 earnings top estimates, while sales missed the same and declined year over year due to generic erosion for the oncology drug Revlimid.
SNYNegative Net Change BMYNegative Net Change PFENegative Net Change NVONegative Net Change
biotechnology pharmaceuticals
BioMarin (BMRN) Q1 Earnings Top, Voxzogo Drives Sales
by Zacks Equity Research
BioMarin (BMRN) reports encouraging first-quarter results, wherein both earnings and sales beat estimates. The rapid uptake of Voxzogo boosts revenues.
SNYNegative Net Change BMRNNegative Net Change LGNDPositive Net Change
biotechnology earnings medical
Alkermes (ALKS) Q1 Earnings & Revenues Beat Estimates
by Zacks Equity Research
Alkermes (ALKS) reports encouraging first-quarter results, wherein both earnings and revenues beat estimates. This is due to strong growth in commercial execution of its proprietary products, Lybalvi and Vivitrol.
JNJNegative Net Change ALKSNegative Net Change LGNDPositive Net Change
biotechnology earnings medical
The Zacks Analyst Blog Highlights Biogen, Incyte, Morphic Therapeutic and bluebird bio
by Zacks Equity Research
Biogen, Incyte, Morphic Therapeutic and bluebird bio are included in this Analyst Blog.
BIIBNegative Net Change INCYNegative Net Change
biotechnology
Will Jakafi Sales Drive a Beat For Incyte (INCY) Q1 Earnings?
by Zacks Equity Research
Incyte's (INCY) first-quarter 2023 earnings are likely to have gained from higher Jakafi sales and incremental sales from newly approved drugs.
NVSNegative Net Change INCYNegative Net Change SGENPositive Net Change ALLOPositive Net Change
biotechnology earnings medical
Ocuphire (OCUP) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Occuphire (OCUP) is expected to provide updates on its proprietary ophthalmic platform for treating refractive and retinal eye disorders, on its first-quarter earnings call.
SGENPositive Net Change ALLOPositive Net Change VTRSNegative Net Change
biotechnology earnings medical
Bristol-Myers (BMY) to Report Q1 Earnings: What+'s in Store?
by Zacks Equity Research
Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q1 results.
SNYNegative Net Change BMYNegative Net Change NVONegative Net Change AMGNNegative Net Change
biotechnology
Assertio (ASRT) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Assertio Therapeutics' (ASRT) Q1 earnings call, investors will likely focus on the sales performance of its rheumatology, pain and inflammation medicines.
RETAPositive Net Change ASRTPositive Net Change AQSTNegative Net Change CELUPositive Net Change
biotechnology earnings medical